FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Ionis NDA for Hereditary Angioedema Attacks

FDA accepts for review an Ionis Pharmaceuticals NDA for donidalorsen, an RNA-targeted treatment for preventing hereditary angioedema attacks.

latest-news-card-1
Human Drugs

FDA Oks Prosthetic Joint Infections Study

FDA gives the green light to Phaxiam Therapeutics for a Phase 2 study (GLORIA) to evaluate its anti-Staphylococcus aureus phages in prosthetic joint i...

latest-news-card-1
Human Drugs

Journey Rosacea Drug Approved by FDA

FDA approves a Journey Medical NDA for Emrosi (minocycline hydrochloride extended release capsules, 40 mg) for treating rosacea inflammatory lesions.

latest-news-card-1
Medical Devices

Percussionaire Recalls Breathing Circuits

Percussionaire recalls certain lots of its Phasitron 5 breathing circuits due to the unexpected presence of nickel coating on one of the circuits comp...

latest-news-card-1
Human Drugs

Opioid REMS to Require Mail-Back Envelopes

FDA approves the addition of mail-back envelopes to the existing opioid analgesic risk evaluation and mitigation strategy to help with safe disposals.

latest-news-card-1
Human Drugs

FDA Taps Comstock Rick for Rare Disease Hub

FDA brings on former Leavitt Partners consultant Amy Comstock Rick to serve as strategic coalitions director for the newly created Rare Disease Innova...

latest-news-card-1
Human Drugs

Aarti Drugs India Plant Hit with FDA-483

A recent inspection of Aarti Drugs Ltds active pharmaceutical ingredient manufacturing plant in India leads to a seven-item FDA Form-483.

latest-news-card-1
Human Drugs

Sen. Rubio Seeks to Ban Certain APIs from China

Senator Marco Rubio (R-FL) urges FDA to take immediate action against two pharmaceutical companies based in Chinas Xinjiang region that allegedly use ...

latest-news-card-1
Human Drugs

Panel Rejects Lexicon Pharma Diabetes Drug

A FDA advisory committee votes against recommending approval for Lexicon Pharmaceuticals' drug Zynquista (sotagliflozin) for adults with Type 1 diabet...

latest-news-card-1
Biologics

FDA Reconsiders CAR-T Product Warning: Marks

FDA backpedals on safety warnings it required on CAR-T cell therapies related to secondary cancers, according to CBER director Peter Marks.